Clinical Trial Detail

NCT ID NCT03015740
Title MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

clear cell renal cell carcinoma

renal cell carcinoma

Therapies

MGCD516 + Nivolumab

Age Groups: adult senior

No variant requirements are available.